Activity update on therapeutics

Article

The increased activity in ophthalmic research is reflected in the long list of clinical studies in their various stages: nearly 300 studies of various aspects of glaucoma and close to 250 studies on ocular surface, cornea and dry eye.

"The increased activity in ophthalmic research is reflected in the long list of clinical studies in their various stages: nearly 300 studies of various aspects of glaucoma and close to 250 studies on ocular surface, cornea and dry eye. Searching the web for retina clinical studies yields about 250 studies, about 190 studies are listed for macular edema and approximately 70 studies for AMD. This clinical bustle heralds the changes that we will soon see in the practice of ophthalmology," so says Sara Krupsky, one of the organiers of the 8th Symposium on Ocular Pharmacology and Therapeutics (ISOPT) in Rome 3–6 December.

"The landscape of ocular therapeutics cannot be fully portrayed without bringing up innovations in ocular drug delivery such as slow release devices implanted in the eye. ISOPT 2009 will accordingly bring to focus the latest novelties in medical devices," continued Dr Krupsky.

The ISOPT programme is geared to provide a continuum, spreading from basic development of therapeutic concepts to their utilization as drugs and technologies in clinical reality. Considerations common to drug development will be discussed with researchers based in academia, clinical investigators, regulatory affairs and industry professionals.

www.isopt2009.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.